tiprankstipranks
Advertisement
Advertisement

ARVN Stock Latest News

Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path
RatingsArvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path
21d ago
ARVN
Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
PremiumRatings
Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
21d ago
ARVN
Arvinas price target raised to $21 from $18 at Citi
PremiumThe Fly
Arvinas price target raised to $21 from $18 at Citi
21d ago
ARVN
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas
PremiumRatings
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas
22d ago
ARVN
Arvinas Reports Positive Phase 1 Data for ARV-102
PremiumCompany Announcements
Arvinas Reports Positive Phase 1 Data for ARV-102
22d ago
8K
ARVN
Arvinas presents data from Phase 1 clinical trial of ARV-102
PremiumThe FlyArvinas presents data from Phase 1 clinical trial of ARV-102
22d ago
ARVN
Arvinas price target raised to $18 from $15 at Citi
Premium
The Fly
Arvinas price target raised to $18 from $15 at Citi
1M ago
ARVN
Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines
Premium
Company Announcements
Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines
1M ago
ARVN
Arvinas price target raised to $11 from $9 at Wedbush
PremiumThe Fly
Arvinas price target raised to $11 from $9 at Wedbush
1M ago
ARVN
Arvinas price target raised to $19 from $14 at Evercore ISI
PremiumThe Fly
Arvinas price target raised to $19 from $14 at Evercore ISI
1M ago
ARVN
Arvinas price target raised to $20 from $16 at Piper Sandler
PremiumThe Fly
Arvinas price target raised to $20 from $16 at Piper Sandler
1M ago
ARVN
Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating
PremiumRatings
Arvinas: Strong Pipeline Momentum, De-Risked Cash Runway, and Attractive Risk‑Reward Support Buy Rating
1M ago
ARVN
Arvinas Earnings Call: High Science, Tight Cash
PremiumCompany AnnouncementsArvinas Earnings Call: High Science, Tight Cash
1M ago
ARVN
Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts
Premium
Ratings
Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts
1M ago
ARVN
Arvinas price target raised to $11 from $9 at Wedbush
Premium
The Fly
Arvinas price target raised to $11 from $9 at Wedbush
1M ago
ARVN
Arvinas sees cash runway into 2H28
PremiumThe Fly
Arvinas sees cash runway into 2H28
1M ago
ARVN
Arvinas reports Q4 EPS ($1.10), consensus (57c)
PremiumThe Fly
Arvinas reports Q4 EPS ($1.10), consensus (57c)
1M ago
ARVN
Arvinas reports Q3 EPS ($1.10), consensus (57c)
PremiumThe Fly
Arvinas reports Q3 EPS ($1.10), consensus (57c)
1M ago
ARVN
ARVN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ARVN Upcoming Earnings Report: What to Expect?
2M ago
ARVN
Arvinas Announces Leadership Transition and New CEO Appointment
PremiumCompany AnnouncementsArvinas Announces Leadership Transition and New CEO Appointment
2M ago
8K
ARVN
Arvinas appoints Randy Teel as President, CEO, director
Premium
The Fly
Arvinas appoints Randy Teel as President, CEO, director
2M ago
ARVN
Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
Premium
The Fly
Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
3M ago
V
MA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >